Industry Research Reports and Market Analysis at MindBranch.com

Therapeutic Peptides in Oncology - Favorable Conditions But Where to Commercialize?

Published By: BioSeeker Group AB
May 2009
R474-343
PDF E-mail From Publisher   $3,400.00
Description

The discovery of new cancer therapeutics has seen a significant shift towards biologicals as an alternative to small molecule drugs. Alternative binding peptide molecules, derived from combinatorial scaffold libraries, are now challenging traditional antibodies. This report identifies the competitive terrain for cancer therapeutic peptides to be wide open from a compound perspective and the opportunity for peptide drugs to challenge other biologicals such as antibodies is real and significant.

This report includes defined and up to date development strategies for 92 cancer therapeutic peptide drugs (>170 projects) within the portfolio of 70 investigators, from Ceased to Marketed. In total the report assesses 30 different cancer indications. The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It serves as an external commercial advocate for pharmaceutical companies’ portfolio planning and new product planning by:
  • Providing you with competitive input to the R&D organization to guide development of early
    • product ideas and ensure efforts are aligned with business objectives
  • Assisting you to make informed decisions in selecting cancer indications that are known to
    • be appropriate for your drug's properties
  • Analyzing, correlating and integrating valuable data sources in order to provide accurate
    • data for valuation of pipeline, in-licensing and new business opportunities
  • Providing you with commercial analytic support for due diligence on in-licensing and
    • acquisition opportunities
  • Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment
This report will also be an important part of creating and implementing a market development plan for any cancer therapeutic peptide drugs to ensure that the optimal market conditions exist by the time the product is commercialized.
Table of Contents
1 Executive Summary
2 About Cancer Highlights
3 Methodologies
4 Table of Contents
4.1 List of Figures
4.2 List of Tables
5 Introduction
5.1 The Scope of this Report
5.2 The Competitive Advantage and Disadvantage of Peptide Drugs
5.3 Definitions
5.4 Abbreviations
6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment
6.1.1 Chaperone Activity Targets
6.1.2 Chemokine Activity Targets
6.1.3 DNA Binding Targets
6.1.4 DNA topoisomerase activity Targets
6.1.5 G-protein Coupled Receptor Activity Targets
6.1.6 Growth Factor Activity Targets
6.1.7 Heat Shock Protein Activity Targets
6.1.8 Hormone Activity Targets
6.1.9 Kinase Activity Targets
6.1.10 Kinase Binding Targets
6.1.11 Kinase Regulator Activity Targets
6.1.12 Ligand-dependent Nuclear Receptor Activity Targets
6.1.13 Metallopeptidase Activity Targets
6.1.14 Molecular Function Unknown Targets
6.1.15 Oxidoreductase Activity Targets
6.1.16 Peptide Hormone Targets
6.1.17 Protease Inhibitor Activity Targets
6.1.18 Protein Binding Targets
6.1.19 Protein Serine/Threonine Kinase Activity Targets
6.1.20 Protein Tyrosine/Serine/Threonine Phosphatase Activity Targets
6.1.21 Protein-Tyrosine Kinase Activity Targets
6.1.22 Protein-Tyrosine Kinase Activity Targets
6.1.23 Receptor Activity Targets
6.1.24 Receptor Signaling Complex Scaffold Activity Targets
6.1.25 RNA Binding Targets
6.1.26 RNA-directed DNA Polymerase Activity Targets
6.1.27 Serine-type Peptidase Activity Targets
6.1.28 Structural Molecule Activity Targets
6.1.29 T cell Receptor Activity Targets
6.1.30 Transcription Factor Activity Targets
6.1.31 Transcription Regulator Activity Targets
6.1.32 Transferase Activity Targets
6.1.33 Transmembrane Receptor Activity Targets
6.1.34 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
6.1.35 Ubiquitin-specific Protease Activity Targets
6.2 The Cancer Genome Project and Peptide Drug Targets
6.2.1 Peptide Drug Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer
6.3 Structure-based Drug Design of Anti-Cancer Peptides is Stimulated by Available Structure
Data on Biological Targets
6.4 Target-Target Interactions among Identified Peptide Targets
6.5 The Drug-Target Interactome
6.6 Protein Expression Levels of Identified Drug Targets of Anti-Cancer Peptide Drugs
6.7 Pathway Analysis of Anti-Cancer Peptide Drug Targets
7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug
7.1 Marketed: New and Unique Target Profiles in the Cancer Therapeutic Peptide Pipeline
7.2 Phase III Clinical Development: New and Unique Target Profiles in the Cancer
Therapeutic Peptide Pipeline
7.3 Phase II Clinical Development: New and Unique Target Profiles in the Cancer Therapeutic
Peptide Pipeline
7.4 Phase I Clinical Development: New and Unique Target Profiles in the Cancer Therapeutic
Peptide Pipeline
7.5 Preclinical Development: New and Unique Target Profiles in the Cancer Therapeutic
Peptide Pipeline
7.6 Development Stage Outline of All Cancer Therapeutic Peptides by Target Profiles
8 Selecting Cancer Indication for Therapeutic Peptides
8.1 Acute Myelogenous Leukemia
8.2 Benign Prostatic Hyperplasia
8.3 Bladder Cancer
8.4 Brain Cancer
8.5 Breast Cancer
8.6 Carcinoid
8.7 Chronic Myelogenous Leukemia
8.8 Colorectal Cancer
8.9 Gastrointestinal Cancer (general)
8.10 Gastrointestinal Stomach Cancer
8.11 Head and Neck Cancer
8.12 Liver Cancer
8.13 Lung Cancer (general)
8.14 Lymphoma (general)
8.15 Melanoma
8.16 Mesothelioma
8.17 Myelodysplastic Syndrome
8.18 Myeloma
8.19 Myoma
8.20 Neuroblastoma
8.21 non-Hodgkin's Lymphoma
8.22 Non-small Cell Lung Cancer
8.23 Ovarian Cancer
8.24 Pancreatic Cancer
8.25 Prostate Cancer
8.26 Renal Cancer
8.27 Sarcoma (general)
8.28 Small Cell Lung Cancer
8.29 Soft Tissue Sarcoma
8.30 Unspecified Cancer Indication
9 Portfolio Planning: Competitive Benchmarking of Cancer Therapeutic Peptide Pipeline by Investigator
9.1 Abbott
9.2 Acceleron Pharma
9.3 Aeterna Zentaris
9.4 Affymax
9.5 Ambrilia Biopharma
9.6 AplaGen Biopharmaceuticals
9.7 ApopLogic Pharmaceuticals
9.8 Apthera
9.9 Ardana
9.10 Attenuon
9.11 AVI BioPharma
9.12 Baxter International
9.13 BioAlliance Pharma
9.14 Biokine Therapeutics
9.15 CanBas
9.16 Cancer Innovations
9.17 Cancer Research Technology
9.18 Celecure
9.19 Celldex Therapeutics
9.20 Chemokine Therapeutics
9.21 Compugen
9.22 Cyclacel
9.23 Dendreon
9.24 DOR BioPharma
9.25 Enkam Pharmaceuticals
9.26 EntreMed
9.27 GlaxoSmithKline
9.28 GP Pharm
9.29 ImmunoCellular Therapeutics
9.30 Immunotope
9.31 ImmuPharma
9.32 Indevus
9.33 Innovive
9.34 Johnson & Johnson
9.35 Mediolanum
9.36 MolMed
9.37 Nektar Therapeutics
9.38 Nemod Biotherapeutics
9.39 Nidus Laboratories
9.40 Norwood Abbey
9.41 Novartis
9.42 OncoTherapy Science
9.43 Oncothyreon
9.44 Pepscan Systems
9.45 PharmaGap
9.46 Pharmexa
9.47 QLT
9.48 Raptor Pharmaceutical
9.49 Receptor BioLogix
9.50 SciClone Pharmaceuticals
9.51 Shire
9.52 Spectrum Pharmaceuticals
9.53 Thallion Pharmaceuticals
9.54 Therion Biologics
9.55 Theryte
9.56 Tigris Pharmaceuticals
9.57 Unigene
9.58 United Biomedical
9.59 Vaxil BioTherapeutics
9.60 Vaxon Biotech
9.61 Voyager Pharmaceutical
9.62 Xigen
9.63 Zelos Therapeutics
9.64 Zensun
9.65 Non-Industrial sources
10 Disclaimer
11 Drug Index
12 Company Index
4.1 List of Figures
Figure 1: Overall Breakdown of the Included Cancer Therapeutic Peptide Pipeline by Cancer Indication and
Stage of Development
Figure 2: Visualization of Target-Target Interactions Among Peptide Drug Targets
Figure 3: The Drug-Protein Interactome of Peptide Drugs
4.2 List of Tables
Table 1: Competitive Pressure Force Among Cancer Therapeutic Peptides
Table 2: Overview of Drug Target Profile Themes
Table 3: Drug Targets of Peptide Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the
Cancer Gene Census
Table 4: Identity of Peptide Drug Targets with Available Biological Structures
Table 5: Number of Target-Target Interactions among Peptide Drug Targets
Table 6: Drug-Protein Interactome Clusters
Table 7: Peptide Drug Targets with Available Protein Expression Profiles
Table 8: Pathway Summary
Table 9: Peptide Drug Targets without any Identified Assigned Pathways
Table 10: Pathway Profile According to BioCarta of Peptide Drug Targets
Table 11: Pathway Profile According to KEGG of Peptide Drug Targets
Table 12: Pathway Profile According to NetPath of Peptide Drug Targets
Table 13: Number of Drug Target Profiles of Peptide Drugs by the Highest Developmental Stage and
Uniqueness
Table 14: Terminally Ceased Drug Target Profiles of Cancer Therapeutic Peptides
Table 15: Top 5 Competitive Peptide Drug Target Profiles
Table 16 New and Unique Target Profiles of Peptide Drugs on the Market
Table 17: New and Unique Target Profiles of Peptide Drugs in Phase III Clinical Development
Table 18: New and Unique Target Profiles of Peptide Drugs in Phase II Clinical Development
Table 19 New and Unique Target Profiles of Peptide Drugs in Phase I Clinical Development
Table 20: New and Unique Target Profiles of Peptide Drugs in Preclinical Development
Table 21: The Progression, Maturity and Competitive Comparison of Cancer Therapeutic Peptide Target Profiles
in Development
Table 22: Competitive Summary of Peptide Drugs by Cancer Indication
Table 23: Drug Target Profiles of Peptides for the Treatment of Acute Myelogenous Leukemia According to
Developmental Stage of Peptide
Table 24: Drug Target Profiles of Peptides for the Treatment of Benign Prostatic Hyperplasia According to
Developmental Stage of Peptide
Table 25: Drug Target Profiles of Peptides for the Treatment of Bladder Cancer According to Developmental
Stage of Peptide
Table 26: Drug Target Profiles of Peptides for the Treatment of Brain Cancer According to Developmental Stage
of Peptide
Table 27: Drug Target Profiles of Peptides for the Treatment of Breast Cancer According to Developmental
Stage of Peptide
Table 28: Drug Target Profiles of Peptides for the Treatment of Carcinoid According to Developmental Stage of
Peptide
Table 29: Drug Target Profiles of Peptides for the Treatment of Chronic Myelogenous Leukemia According to
Developmental Stage of Peptide
Table 30: Drug Target Profiles of Peptides for the Treatment of Colorectal Cancer According to Developmental
Stage of Peptide
Table 31: Drug Target Profiles of Peptides for the Treatment of Gastrointestinal Cancer (general) According to
Developmental Stage of Peptide
Table 32: Drug Target Profiles of Peptides for the Treatment of Gastrointestinal Stomach Cancer According to
Developmental Stage of Peptide
Table 33: Drug Target Profiles of Peptides for the Treatment of Head and Neck Cancer According to
Developmental Stage of Peptide
Table 34: Drug Target Profiles of Peptides for the Treatment of Liver Cancer According to Developmental Stage
of Peptide
Table 35: Drug Target Profiles of Peptides for the Treatment of Lung Cancer (general) According to
Developmental Stage of Peptide
Table 36: Drug Target Profiles of Peptides for the Treatment of Lymphoma (general) According to
Developmental Stage of Peptide
Table 37: Drug Target Profiles of Peptides for the Treatment of Melanoma According to Developmental Stage
of Peptide
Table 38: Drug Target Profiles of Peptides for the Treatment of Mesothelioma According to Developmental
Stage of Peptide
Table 39: Drug Target Profiles of Peptides for the Treatment of Myelodysplastic Syndrome According to
Developmental Stage of Peptide
4 Therapeutic Peptides in Oncology -Favorable Conditions But Where to
Commercialize?
16 Cancer Highlights No 8 Vol 8 2009| BioSeeker Group AB ©
Table 40: Drug Target Profiles of Peptides for the Treatment of Myeloma According to Developmental Stage of
Peptide
Table 41: Drug Target Profiles of Peptides for the Treatment of Myoma According to Developmental Stage of
Peptide
Table 42: Drug Target Profiles of Peptides for the Treatment of Neuroblastoma According to Developmental
Stage of Peptide
Table 43: Drug Target Profiles of Peptides for the Treatment of non-Hodgkin's Lymphoma According to
Developmental Stage of Peptide
Table 44: Drug Target Profiles of Peptides for the Treatment of Non-small Cell Lung Cancer According to
Developmental Stage of Peptide
Table 45: Drug Target Profiles of Peptides for the Treatment of Ovarian Cancer According to Developmental
Stage of Peptide
Table 46: Drug Target Profiles of Peptides for the Treatment of Pancreatic Cancer According to Developmental
Stage of Peptide
Table 47: Drug Target Profiles of Peptides for the Treatment of Prostate Cancer According to Developmental
Stage of Peptide
Table 48: Drug Target Profiles of Peptides for the Treatment of Renal Cancer According to Developmental Stage
of Peptide
Table 49: Drug Target Profiles of Peptides for the Treatment of Sarcoma (general) According to Developmental
Stage of Peptide
Table 50: Drug Target Profiles of Peptides for the Treatment of Small Cell Lung Cancer According to
Developmental Stage of Peptide
Table 51: Drug Target Profiles of Peptides for the Treatment of Soft Tissue Sarcoma According to
Developmental Stage of Peptide
Table 52: Drug Target Profiles of Peptides for the Treatment of Not Specified Cancer Indication According to
Developmental Stage of Peptide
Table 53: Abbott's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out
Table 54: Acceleron Pharma's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-
Out
Table 55: Aeterna Zentaris’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out
Table 56: Affymax's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out
Table 57: Ambrilia Biopharma's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive
Fall-Out
Table 58: AplaGen Biopharmaceuticals’ Included Cancer Therapeutic Peptide Pipeline Composition and
Competitive Fall-Out
Table of Contents
BioSeeker Group AB © 2009 | www.bioseeker.com
Table 59: ApopLogic Pharmaceuticals’ Included Cancer Therapeutic Peptide Pipeline Composition and
Competitive Fall-Out
Table 60: Apthera's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out
Table 61: Ardana's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out
Table 62: Attenuon's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out
Table 63: AVI BioPharma's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out
Table 64: Baxter International's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive
Fall-Out
Table 65: BioAlliance Pharma's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-
Out
Table 66: Biokine Therapeutics’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive
Fall-Out
Table 67: CanBas’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out
Table 68: Cancer Innovations’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-
Out
Table 69: Cancer Research Technology's Included Cancer Therapeutic Peptide Pipeline Composition and
Competitive Fall-Out
Table 70: Celecure's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out
Table 71: Celldex Therapeutics’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-
Out
Table 72: Chemokine Therapeutics’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive
Fall-Out
Table 73: Compugen's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out .
Table 74: Cyclacel's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out
Table 75: Dendreon's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out
Table 76: DOR BioPharma's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-
Out
Table 77: Enkam Pharmaceuticals’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive
Fall-Out
Table 78: EntreMed's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out
Table 79: GlaxoSmithKline's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-
Out
Table 80: GP Pharm's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out
Table 81: ImmunoCellular Therapeutics’ Included Cancer Therapeutic Peptide Pipeline Composition and
Competitive Fall-Out
4 Therapeutic Peptides in Oncology -Favorable Conditions But Where to
Commercialize?
18 Cancer Highlights No 8 Vol 8 2009| BioSeeker Group AB ©
Table 82: Immunotope's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out
Table 83: ImmuPharma's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out
Table 84: Indevus’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out
Table 85: Innovive's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out
Table 86: Johnson & Johnson's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-
Out
Table 87: Mediolanum's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out
Table 88: MolMed's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out
Table 89: Nektar Therapeutics’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-
Out
Table 90: Nemod Biotherapeutics’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive
Fall-Out
Table 91: Nidus Laboratories’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-
Out
Table 92: Norwood Abbey's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out
Table 93: Novartis’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out
Table 94: OncoTherapy Science's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive
Fall-Out
Table 95: Oncothyreon's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out
Table 96: Pepscan Systems’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out
Table 97: PharmaGap's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out
Table 98: Pharmexa's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out ..
Table 99: QLT's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out
Table 100: Raptor Pharmaceutical's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive
Fall-Out
Table 101: Receptor BioLogix's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-
Out
Table 102: SciClone Pharmaceuticals’ Included Cancer Therapeutic Peptide Pipeline Composition and
Competitive Fall-Out
Table 103: Shire's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out
Table of Contents
BioSeeker Group AB © 2009 | www.bioseeker.com
Table 104: Spectrum Pharmaceuticals’ Included Cancer Therapeutic Peptide Pipeline Composition and
Competitive Fall-Out
Table 105: Thallion Pharmaceuticals’ Included Cancer Therapeutic Peptide Pipeline Composition and
Competitive Fall-Out
Table 106: Therion Biologics’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-
Out
Table 107: Theryte's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out
Table 108: Tigris Pharmaceuticals’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive
Fall-Out
Table 109: Unigene's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out
Table 110: United Biomedical's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-
Out
Table 111: Vaxil BioTherapeutics’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive
Fall-Out
Table 112: Vaxon Biotech's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out
Table 113: Voyager Pharmaceutical's Included Cancer Therapeutic Peptide Pipeline Composition and
Competitive Fall-Out
Table 114: Xigen's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out
Table 115: Zelos Therapeutics’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-
Out
Table 116: Zensun's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out
Table 117: Non-industrial source's Included Cancer Therapeutic Peptide Pipeline Composition and Competitive
Fall-Out
Order Form
       * Please reference product number R474-343 when ordering or inquiring.
PUBLICATION:   Therapeutic Peptides in Oncology - Favorable Conditions But Where to Commercialize?
QTY. FORMAT PRICE TOTAL
  PDF E-mail From Publisher$3,400.00   
  SUBTOTAL   
SHIPPING CHARGES
 (U.S. $25, Canada $35, Int'l $65) 		 
TOTAL  

CONTACT INFORMATION
PAYMENT INFORMATION
Name ____________________________________________ MasterCard VISA AmEx Discover

__________________________________
Account number                 Exp. date

__________________________________
Signature

__________________________________
Email

Please invoice
      (shipment on receipt of payment)
Payment enclosed
*CHECKS / WIRE TRANSFERS:
Checks must be paid in U.S. funds.
Please call for details.
Company ____________________________________________
Job Title ____________________________________________
Address ____________________________________________
City ____________________________________________
Company ____________________________________________
State ______________________________   Zip__________
Country ____________________________________________
Phone ____________________________________________
MindBranch, Inc.,     131 Ashland St., Suite 200 North Adams, MA  01247       tel: 800-774-4410     fax: +1-413-664-9791     www.mindbranch.com